Treatment of Major Depression With Nortriptyline and Paroxetine in Patients With Ischemic Heart Disease

摘要: OBJECTIVE: This study compared the efficacy, tolerability, and safety of paroxetine nortriptyline in depressed patients with ischemic heart disease. METHOD: After a 2-week, single-blind placebo lead-in phase, 81 outpatients DSM-III-R-defined nonpsychotic unipolar major depression disease were randomly assigned to double-blind treatment or for 6 weeks. Paroxetine was administered at fixed-flexible dose 20–30 mg/day. Nortriptyline adjusted use blood-level monitoring reach plasma concentration 50–150 ng/ml. RESULTS: Twenty-seven 41 who started 29 40 had an improvement least 50% their Hamilton Depression Rating Scale scores. Significantly more taking discontinued prematurely (35% versus 10%), adverse events resulting termination (2...